Trijardy XR (Empaglifloz/Linaglip/Metformin) Patent Expiration, LOE Window & CMS Spending

Trijardy XR (Empaglifloz/Linaglip/Metformin) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2029-02-01 (last listed 2037-12-08), 0 AB generics, $115.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBoehringer Ingelheim
FDA Application & PathwayN212614 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2029-02-01
Last Listed Patent or Exclusivity Date2037-12-08
Orange Book Patents (*PED Extensions)28 patents (11 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$115.8M
2024 Medicare Part D Spend$99.1M
2024 Medicaid Spend$16.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.